Risk behaviour and HTLV‐1 seropositivity in injecting drug users
G Rezza(Istituto Superiore di Sanità), P. Verani(Istituto Superiore di Sanità), Patrizio Pezzotti(Istituto Superiore di Sanità), Francesca Menniti‐Ippolito(National Institute of Health), Mario Tumbarello(University of Siena), Caterina Uberti‐Foppa(Vita-Salute San Raffaele University), Fausto Trrn(Istituto Superiore di Sanità), Adriano Lazzarin(Vita-Salute San Raffaele University)
Cited by 2
Related Papers
European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine)
|Clinical Microbiology and Infection|2021|1k
Efficacy of Enfuvirtide in Patients Infected with Drug-Resistant HIV-1 in Europe and Australia
|New England Journal of Medicine|2003|653
Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study
|The Lancet Infectious Diseases|2017|521
Self-Reported Symptoms and Medication Side Effects Influence Adherence to Highly Active Antiretroviral Therapy in Persons With HIV Infection
|JAIDS Journal of Acquired Immune Deficiency Syndromes|2001|470